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                                                         Swine erysipelas is a bacterial disease of world-wide importance. Immunization is 
very effective in preventing this infection. Vaccines have already been used for 50 years and are safe, efficient and 
easy to produce. Both inactivated and attenuated vaccines are available to prevent development of clinical signs of 
swine erysipelas. However, live attenuated vaccines cannot be used in any epizootic situation. For a long time in 
Albania it has produced an attenuated live vaccine against Erysipelothrix rhusiopathiae. For a long time in Albania it 
has produced an attenuated live vaccine against Erysipelothrix rhusiopathiae. This vaccine had a limited validity and 
occasionally gave the post vaccination incidents. To improve the parameters of this vaccine, and to extend its period 
of validity of we thought to produce a inactivated oily and lyophilized vaccine against Erysipelothrix rhusiopathiae. 
This constitutes the purpose of this study. 
 
Introduction  
Swine erysipelas is an important infectious disease of bacterial etiology, widespread in pigs 
of the new age. The clinical and pathological features of the disease have been well-described 
(Wood and Henderson, 2006). Since a character zoonotic disease, it represents a problem for 
public health and veterinary services. 
 
Immunizing pigs against swine erysipelas using live or killed vaccines has been a common 
practice for many years and commercial products are generally considered to be efficacious 
(Haesebrouck et al, 2004, Neumann et al. 2008).  
 
Prevention of swine erysipelas is best accomplished by immunization programs. Current 
vaccines are based on E. rhusiopathiae serotypes 1 or 2 and are either inactivated bacterins for 
intramuscular injection or attenuated (avirulent live) vaccines designed for whole herd mass 
treatment via drinking water. Most bacterins are serotype 2 (Eamens et al. 2006; Wood 1979) and 
most attenuated live vaccines contain serotype 1a isolates (Opriessnig et al. 2004). Vaccination is 
generally effective in preventing swine erysipelas and the duration of immunity varies between 6 
and 12 months for both correctly administered bacterins and avirulent vaccines (Swan and Lindsey 
1998). Vaccination may not be as effective in preventing chronic arthritis since sequestration of E. 
rhusiopathiae in the cytoplasm of chondrocytes of articular cartilage may provide protection from 
host immunity.  
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Vaccination of breeding animals reportedly reduces the incidence of periparturient vulval 
discharge, decreases farrowing intervals, and increases the numbers of live-born pigs in clinically 
affected herds (Gertenbach and Bilkei 2002). 
 
In Albania, for immunization of pigs against Erysipelotrirx rhusiopathiae using a vaccine 
with VR2 strain of Erysipelothrix rhusiopathiae. This vaccine has a short-term use (effectively 45 
days). Its practical application has some difficulty. Specific prophylaxis with this vaccine applied 
only to heads free of erysipelas infection. In herds of pigs where infection has exploded the 
application of this vaccine aggravate the situation. Determination the effectiveness of this vaccine 
performed only on animals homologue, therefore financial cost is very high. To improve the 
parameters of this vaccine we undertook the study with the above title. 
 
Materials and methods 
 
Production of vaccine emulsions 
 
For the production of lyophilized vaccine was used Erysipelothrix  rhusiopathiae- VR2, 
vaccine strain. By the vial containing the vaccine VR2 strain were carried out planting on agar 
media, liquid media and Taroc media. After the planting, the microbial cultures were incubated in 
the thermostat at 37
o
C for 24 hours.  After 24 hours, microbial cultures were controlled 
macroscopically and microscopically for purity. Subsequently, was carried out rinsing of microbial 
cultures with normal blood serum sterilized, benefiting base emulsion, which was tested for purity 
by means of cultures. This emulsion was used for planting of "Roux" plates. So, they were planted 
20 Roux plates that were placed in thermostat for incubation. After 24 hours Roux plates were 
pulled from the thermostat and were controlled for microbial purity. 10 Roux plates were rinsed 
with protector gelatine–saccharose and 10 others with normal horse serum sterilized for 1 hour at 
56
o
 C, for 3 consecutive days. After the collection of emulsions, for each protector, were carried 
out control of agar, and Taroc and liquid media for purity. Emulsions, resulting microbiologically 
pure was placed in vials of 30 ml, where each vial contained 8 ml emulsion. Vials of vaccine were 




Study and determination of parameters of lyophilisation of vaccine against swine erysipelas 
 
They studied and determined parameters of lyophilized vaccine as follows:  
- The temperature and the time required for freezing 
- The temperature of sublimation and its duration 
- The duration of conditioning of vaccine after sublimation and temperature of conditioning 
- Temperature of drying and rewarming   of vaccine 
- The level of vacuum in which the vaccine was closed 
 
The data are presented in table. 1 
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Study and determination of the most appropriate protector of lyophilized vaccine 
 
Were produced 2 series of vaccines by rinsing Roux plates with two types of protectors 
- The protector gelatin-saccharose 
- Normal horse serum (tyndallized at 56
o
C for 1 hour) 
 
In each plate were added 15-20 ml protector and were collected in balloons sterile. Vaccine 
emulsions were controlled for purity by means of agar cultures, and Taroc media and liquid media. 
Once the resulted sterile, were entered in the vial of 30 ml, where in the each vial was introduced 
by 8 ml emulsion of vaccine. Bottles containing emulsion of vaccine were placed in lyophilisation 
apparatus for drying. The formula of protector gelatin- saccharose is: Gelatin 1%, Saccharose 
10%, Distilled Water until 100ml. Sterilization was carried out in the 0.5 atmosphere for 45 
minutes. After completing the procedure of lyophilisation, vaccines were controlled for purity, 
vacuum level, the percentage of residual moisture, appearance  of lyophilized mass and microbial 
concentration in the time immediately after drying, and in different time intervals (after 
lyophilisation). On the basis of the results obtained was determined which one protector appears as 
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Determination of microbial concentration and validity of vaccine 
 




, according to the model 
of classic dilution 9 + 1. In Petri dishes with terrain TSA (simple agar) were made planting using 1 
ml for each dilution and adding 0.5 ml of normal horse serum. Plates were held at room 
temperature for about 30 minutes and then were placed in thermostat for cultivation.  
 
After a cultivation period of 48-72 hours, was the determination of microbial concentration 
of lyophilized vaccine for every one protector used. With the same methodology was determined 
the validity of vaccines in periods of 3, 6, 8 and 12 months after lyophilisation. The data obtained 
were processed statistically by the formula: 
 
C1 + C2 + C3 
                                           X =     
         N1x 10
-6
 + N2 x 10
-7
 + N3 x 10
-8 
 
Where: X = average for 1 ml suspension colonies base 
C1 = amount of colonies at 10-6 dilution 
C2 = amount of colonies at 10-7 dilution 
C3 = amount of colonies at 10-8 dilution 
N1 = number of Petri dishes by diluting 10-6 
N2 = number of Petri dishes by diluting 10-7 
N3 = the number of Petri dishes by diluting 10-8 
 
The vaccine was tested for purity, to the residual moisture, by the recognized laboratory 
methods.  
 
Determination of adequate solvent of vaccine was made by injecting vaccine in laboratory 
mouse 
 
Results and Discussion 
 
Doing according to the methodology described above, the lyophilized vaccine was 
produced. Are defined the parameters of lyophilisation, which are presented in the table: 
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Tab. 1. Technological processes and defined parameters of lyophilisation 
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Sublimation temperature of the vaccine and 
its the duration (at this stage of the process 






























 C 5 8 
The vacuum level that should have the 
vaccine (expressed in micron 
- - 0.5µ 1 
 
The vaccine proved to be pure, safe, with residual moisture 1.2% and 0.5 micron vacuum 
level by all parameters specified by the relevant literature. Microbial concentration of the 
lyophilized vaccine was 900 million microbial cells for 1 ml, and microbial concentration of the 
emulsions before lyophilisation was 1.098 billion microbial cells. So there was a decrease 
approximately 18% of microbial cells, a level acceptable to the vaccine of this type. As for 
protector of the lyophilized vaccine was used protectors described of the methodology above 
(protector gelatin + saccharose, and normal  horse tindallized serum). The data obtained are 
presented in the table 3. 
 
Table 3. Determining the concentration of microbial cell vaccine (per ml) depending on the 

























1.098.000.000 724.000.000 66 
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From the data it resulted that protector gelatin-saccharose is more suitable for 
lyophilization of the vaccine, because in this case there is a decrease of microbial cells per ml 
approximately 16% less than when used as protector normal horse serum. Determination of shelf 
life of the the lyophilized vaccine was realized by determining the concentration of microbial cells 
for ml vaccine at different periods of time after lyophilisation. Results are presented in table 4.  
 
Table 4. Determination of the concentration of microbial cells per ml vaccine after different 
periods of time 
 




after  lyophilisation 
Microbial concentration for 1 ml of lyophilized 
vaccine after different periods of time 










724.000.000 640.000.000 580.000.000 420.000.000 
 
Based on the data obtained and the concentration of microbial for ml that should be 1 ml 
vaccine, to provide a power protection defined (protection against 1 infectious dose or minimo 
lethal), the decline in concentration microbial for 1 ml of 20% to the initial concentration does not 
affect the protective power of the vaccine because 1 dose of vaccine to induce a certain immunity 




It was produced lyophilized vaccine against swine erysipelas with a 1 year shelf life. 
Protective power (immunogenicity) of this vaccine is similar to the liquid vaccine (Çarçani, 1994). 
To eliminate any accident vaccinated because VR2 has a certain strain virulence, used as a solvent 
0,01% agar- agar. Since produced, vaccine lyophilized was tested for purity (it resulted pure) for 
percentage of moisture residual (was 1.2% moisture), and was determined the solvent better for it. 
(saline solution + 0.01% of agar that plays also an adjuvant). 
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